| Ytd | -38.02% | |
| 1y | -38.02% |
| Open | 9.36 | Prev Close | 9.22 | Low | 8.96 | High | 9.45 | Mkt Cap | 447.17M |
| Vol | 102.32K | Avg Vol | 139.21K | EPS | -2.07 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 12.62 | 200-d Avg | 12.44 | 1yr Est | 0.00 |
AGMB News
AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in F
Gainers Elutia (NASDAQ:ELUT) stock moved upwards by 17.2% to $0.94 during Thursday's after-mark
Agomab Therapeutics NV (NASDAQ:AGMB) reported results from the 48-week open-label extension portion
Agomab Therapeutics reports positive 48-week Phase 2a trial data for ontunisertib in patients with f
Gainers Nexalin Technology (NASDAQ:NXL) shares increased by 77.8% to $7.61 during Thursday's re
Agomab Therapeutics NV (‘Agomab’) a clinical-stage biopharmaceutical company focused on fibro-inflam
-- Favorable safety and tolerability profile maintained through up to 60 weeks of treatment with ont
AgomAb Therapeutics NV (NASDAQ: AGMB - Get Free Report) has received a consensus recommendation of "
Agomab Therapeutics targets fibrotic strictures in Crohn's disease, aiming to create a new treatment
-- Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447 -- --
Agomab announced shareholders approved all resolutions submitted for consideration at the Company's
Antwerp, Belgium, September 3, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-s
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
Analysts change outlook on top names. See all rating changes, including upgrades/downgrades/initiati
Piper Sandler analyst Yasmeen Rahimi initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with
Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Chec
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on AgomAb Therapeutics (NASDAQ:AG
Antwerp, Belgium, August 10, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"
-- Regulatory alignment with U. S. Food and Drug Administration (FDA) on key elements of NOV-ERA Pha
B. Riley Securities analyst William Woods initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB)
-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phas
-- Regulatory alignment with U. S. Food and Drug Administration (FDA) on key elements of NOV-ERA Pha
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
Top analysts changed ratings on top stocks, including Conexeu, CRDO, AGMB, SPCX, and FTH. See what a
HC Wainwright & Co. analyst Patrick R. Trucchio initiates coverage on AgomAb Therapeutics (NA
AgomAb Therapeutics offers high-risk, high-reward potential driven by two late-stage immunology drug
Antwerp, Belgium, May 27, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage
Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage
-- Cash and Cash Investments at December 31, 2025 of €116. 5 Million and Gross Proceeds of $208 Mill
Agomab Therapeutics NV (NASDAQ:AGMB) ("'Agomab'"), a clinical-stage biopharmaceutica
Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“'Agomab'”), a clinical-st
Leerink Partners analyst Thomas Smith initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) wit
JP Morgan analyst Anupam Rama initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Over
Top Wall Street analysts changed outlook on top names. Check out analyst ratings page for all change
Morgan Stanley analyst Judah Frommer initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with
